{"id":"NCT03371082","sponsor":"Gan and Lee Pharmaceuticals, USA","briefTitle":"Gan & Lee Insulin Glargine Target Type (1) Evaluating Research","officialTitle":"An Open Label, Randomized, Multicenter, Phase 3 Study to Compare the Immunogenicity, Efficacy and Safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus in Adult Subjects With Type 1 Diabetes Mellitus.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-31","primaryCompletion":"2019-08-19","completion":"2019-08-19","firstPosted":"2017-12-13","resultsPosted":"2024-05-14","lastUpdate":"2024-05-14"},"enrollment":576,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"BIOLOGICAL","name":"Gan & Lee Insulin Glargine Injection","otherNames":[]},{"type":"BIOLOGICAL","name":"Lantus®","otherNames":[]}],"arms":[{"label":"Gan & Lee Insulin Glargine Injection","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n•To evaluate equivalence of Gan \\& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity\n\nSecondary Objective:\n\nImmunogenicity:\n\n• To evaluate the percentage of subjects with negative anti-insulin antibodies (AIAs) at baseline who develop confirmed positive AIA up to Week 26, the percentage of baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and percentage of subjects who develop confirmed positive AIA up to visit Week 26 of Gan \\& Lee Insulin Glargine Injection in comparison with that of Lantus®.\n\nSafety:\n\n•To evaluate the safety of Gan \\& Lee Insulin Glargine Injection in comparison with that of Lantus®.\n\nEfficacy:\n\n•To evaluate the efficacy of Gan \\& Lee Insulin Glargine Injection in comparison with that of Lantus®.","primaryOutcome":{"measure":"Treatment-induced Anti-Insulin Antibody (TI-AIA)","timeFrame":"Assessed up to Week 26","effectByArm":[{"arm":"Gan & Lee Insulin Glargine Injection","deltaMin":4.8,"sd":88.88},{"arm":"Lantus®","deltaMin":42.5,"sd":332.9}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":85,"countries":["United States","Czechia","Germany","Hungary","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":287},"commonTop":["Hypoglycemia","Weight increase","Fatigue","Hyperglycemia","Blood creatine phosphokinase increased"]}}